Nicotine and Parkinson's disease: Implications for therapy
Identifieur interne : 002734 ( Main/Exploration ); précédent : 002733; suivant : 002735Nicotine and Parkinson's disease: Implications for therapy
Auteurs : Maryka Quik [États-Unis] ; Kathryn O'Leary [États-Unis] ; Caroline M. Tanner [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2008-09.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Tabagisme.
English descriptors
- KwdEn :
- Animals, Antiparkinson Agents (therapeutic use), Dyskinesia, Humans, Levodopa, L‐dopa, Nervous system diseases, Nicotine, Nicotine (therapeutic use), Nicotinic receptor, Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson disease, Tobacco smoking, Treatment, dyskinesias, neuroprotection, nicotinic receptors, smoking, striatum.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Nicotine.
- drug therapy : Parkinson Disease.
- epidemiology : Parkinson Disease.
- Animals, Humans.
Abstract
Accumulating evidence suggests that nicotine, a drug that stimulates nicotinic acetylcholine receptors, may be of therapeutic value in Parkinson's disease. Beneficial effects may be several‐fold. One of these is a protective action against nigrostriatal damage. This possibility stems from the results of epidemiological studies that consistently demonstrate an inverse correlation between tobacco use and Parkinson's disease. This reduced incidence of Parkinson's disease has been attributed to the nicotine in tobacco products, at least in part, based on experimental work showing a protective effect of nicotine against toxic insults. Second, several studies suggest a symptomatic effect of nicotine in Parkinson's disease, although effects are small and somewhat variable. Third, recent data in nonhuman primates show that nicotine attenuates levodopa‐induced dyskinesias, a debilitating side effect that develops in the majority of patients on levodopa therapy. Collectively, these observations suggest that nicotine or CNS selective nicotinic receptor ligands hold promise for Parkinson's disease therapy to reduce disease progression, improve symptoms, and/or decrease levodopa‐induced dyskinesias. © 2007 Movement Disorder Society
Url:
- https://api.istex.fr/document/3F9FB8B92C54E896BD388C91549EC7D0FCBE9987/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430096
DOI: 10.1002/mds.21900
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000A89
- to stream Istex, to step Curation: 000A89
- to stream Istex, to step Checkpoint: 001290
- to stream Pmc, to step Corpus: 000202
- to stream Pmc, to step Curation: 000202
- to stream Pmc, to step Checkpoint: 000437
- to stream PubMed, to step Corpus: 002116
- to stream PubMed, to step Curation: 002116
- to stream PubMed, to step Checkpoint: 002185
- to stream Ncbi, to step Merge: 002247
- to stream Ncbi, to step Curation: 002247
- to stream Ncbi, to step Checkpoint: 002247
- to stream Main, to step Merge: 003312
- to stream PascalFrancis, to step Corpus: 001123
- to stream PascalFrancis, to step Curation: 001B96
- to stream PascalFrancis, to step Checkpoint: 001167
- to stream Main, to step Merge: 003775
- to stream Main, to step Curation: 002734
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nicotine and Parkinson's disease: Implications for therapy</title><author><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name></author><author><name sortKey="O Leary, Kathryn" sort="O Leary, Kathryn" uniqKey="O Leary K" first="Kathryn" last="O'Leary">Kathryn O'Leary</name></author><author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3F9FB8B92C54E896BD388C91549EC7D0FCBE9987</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.21900</idno><idno type="url">https://api.istex.fr/document/3F9FB8B92C54E896BD388C91549EC7D0FCBE9987/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000A89</idno><idno type="wicri:Area/Istex/Curation">000A89</idno><idno type="wicri:Area/Istex/Checkpoint">001290</idno><idno type="wicri:doubleKey">0885-3185:2008:Quik M:nicotine:and:parkinson</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430096</idno><idno type="RBID">PMC:4430096</idno><idno type="wicri:Area/Pmc/Corpus">000202</idno><idno type="wicri:Area/Pmc/Curation">000202</idno><idno type="wicri:Area/Pmc/Checkpoint">000437</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">002116</idno><idno type="wicri:Area/PubMed/Curation">002116</idno><idno type="wicri:Area/PubMed/Checkpoint">002185</idno><idno type="wicri:Area/Ncbi/Merge">002247</idno><idno type="wicri:Area/Ncbi/Curation">002247</idno><idno type="wicri:Area/Ncbi/Checkpoint">002247</idno><idno type="wicri:doubleKey">0885-3185:2008:Quik M:nicotine:and:parkinson</idno><idno type="wicri:Area/Main/Merge">003312</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:08-0487362</idno><idno type="wicri:Area/PascalFrancis/Corpus">001123</idno><idno type="wicri:Area/PascalFrancis/Curation">001B96</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001167</idno><idno type="wicri:doubleKey">0885-3185:2008:Quik M:nicotine:and:parkinson</idno><idno type="wicri:Area/Main/Merge">003775</idno><idno type="wicri:Area/Main/Curation">002734</idno><idno type="wicri:Area/Main/Exploration">002734</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Nicotine and Parkinson's disease: Implications for therapy</title><author><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Parkinson's Institute, Sunnyvale, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="O Leary, Kathryn" sort="O Leary, Kathryn" uniqKey="O Leary K" first="Kathryn" last="O'Leary">Kathryn O'Leary</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Parkinson's Institute, Sunnyvale, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Parkinson's Institute, Sunnyvale, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-09">2008-09</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1641">1641</biblScope><biblScope unit="page" to="1652">1652</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">3F9FB8B92C54E896BD388C91549EC7D0FCBE9987</idno><idno type="DOI">10.1002/mds.21900</idno><idno type="ArticleID">MDS21900</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiparkinson Agents (therapeutic use)</term><term>Dyskinesia</term><term>Humans</term><term>Levodopa</term><term>L‐dopa</term><term>Nervous system diseases</term><term>Nicotine</term><term>Nicotine (therapeutic use)</term><term>Nicotinic receptor</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (epidemiology)</term><term>Parkinson disease</term><term>Tobacco smoking</term><term>Treatment</term><term>dyskinesias</term><term>neuroprotection</term><term>nicotinic receptors</term><term>smoking</term><term>striatum</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Nicotine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term><term>Lévodopa</term><term>Maladie de Parkinson</term><term>Nicotine</term><term>Pathologie du système nerveux</term><term>Récepteur nicotinique</term><term>Tabagisme</term><term>Traitement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Tabagisme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Accumulating evidence suggests that nicotine, a drug that stimulates nicotinic acetylcholine receptors, may be of therapeutic value in Parkinson's disease. Beneficial effects may be several‐fold. One of these is a protective action against nigrostriatal damage. This possibility stems from the results of epidemiological studies that consistently demonstrate an inverse correlation between tobacco use and Parkinson's disease. This reduced incidence of Parkinson's disease has been attributed to the nicotine in tobacco products, at least in part, based on experimental work showing a protective effect of nicotine against toxic insults. Second, several studies suggest a symptomatic effect of nicotine in Parkinson's disease, although effects are small and somewhat variable. Third, recent data in nonhuman primates show that nicotine attenuates levodopa‐induced dyskinesias, a debilitating side effect that develops in the majority of patients on levodopa therapy. Collectively, these observations suggest that nicotine or CNS selective nicotinic receptor ligands hold promise for Parkinson's disease therapy to reduce disease progression, improve symptoms, and/or decrease levodopa‐induced dyskinesias. © 2007 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name></region><name sortKey="O Leary, Kathryn" sort="O Leary, Kathryn" uniqKey="O Leary K" first="Kathryn" last="O'Leary">Kathryn O'Leary</name><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002734 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002734 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:3F9FB8B92C54E896BD388C91549EC7D0FCBE9987
|texte= Nicotine and Parkinson's disease: Implications for therapy
}}
| This area was generated with Dilib version V0.6.23. |  |